Click here to close
Hello! We notice that you are using Internet Explorer, which is not supported by Xenbase and may cause the site to display incorrectly.
We suggest using a current version of Chrome,
FireFox, or Safari.
Investigations into the role of the Plasmodium falciparum SERCA (PfATP6) L263E mutation in artemisinin action and resistance.
Valderramos SG
,
Scanfeld D
,
Uhlemann AC
,
Fidock DA
,
Krishna S
.
Abstract
Artemisinin-based combination therapies (ACTs) are highly effective for the treatment of Plasmodium falciparum malaria, yet their sustained efficacy is threatened by the potential spread of parasite resistance. Recent studies have provided evidence that artemisinins can inhibit the function of PfATP6, the P. falciparum ortholog of the ER calcium pump SERCA, when expressed in Xenopus laevis oocytes. Inhibition was significantly reduced in an L263E variant, which introduced the mammalian residue into a putative drug-binding pocket. To test the hypothesis that this single mutation could decrease P. falciparum susceptibility to artemisinins, we implemented an allelic-exchange strategy to replace the wild-type pfatp6 allele by a variant allele encoding L263E. Transfected P. falciparum clones were screened by PCR analysis for disruption of the endogenous locus and introduction of the mutant L263E allele under the transcriptional control of a calmodulin promoter. Expression of the mutant allele was demonstrated by reverse transcriptase (RT) PCR and verified by sequence analysis. Parasite clones expressing wild-type or L263E variant PfATP6 showed no significant difference in 50% inhibitory concentrations (IC(50)s) for artemisinin or its derivatives dihydroartemisinin and artesunate. Nonetheless, hierarchical clustering analysis revealed a trend toward reduced susceptibility that neared significance (artemisinin, P approximately = 0.1; dihydroartemisinin, P = 0.053 and P = 0.085; and artesunate, P = 0.082 and P = 0.162 for the D10 and 7G8 lines, respectively). Notable differences in the distribution of normalized IC(50)s provided evidence of decreased responsiveness to artemisinin and dihydroartemisinin (P = 0.02 for the D10 and 7G8 lines), but not to artesunate in parasites expressing mutant PfATP6.
Akompong,
Artemisinin and its derivatives are transported by a vacuolar-network of Plasmodium falciparum and their anti-malarial activities are additive with toxic sphingolipid analogues that block the network.
1999, Pubmed
Akompong,
Artemisinin and its derivatives are transported by a vacuolar-network of Plasmodium falciparum and their anti-malarial activities are additive with toxic sphingolipid analogues that block the network.
1999,
Pubmed
Asawamahasakda,
Reaction of antimalarial endoperoxides with specific parasite proteins.
1994,
Pubmed
Bertaux,
New PfATP6 mutations found in Plasmodium falciparum isolates from Vietnam.
2009,
Pubmed
Bhisutthibhan,
Immunoprecipitation of [(3)H]dihydroartemisinin translationally controlled tumor protein (TCTP) adducts from Plasmodium falciparum-infected erythrocytes by using anti-TCTP antibodies.
2001,
Pubmed
Bozdech,
The transcriptome of the intraerythrocytic developmental cycle of Plasmodium falciparum.
2003,
Pubmed
Bray,
Quinolines and artemisinin: chemistry, biology and history.
2005,
Pubmed
Chavchich,
Role of pfmdr1 amplification and expression in induction of resistance to artemisinin derivatives in Plasmodium falciparum.
2010,
Pubmed
Coghi,
Interaction of artemisinins with oxyhemoglobin Hb-FeII, Hb-FeII, carboxyHb-FeII, heme-FeII, and carboxyheme FeII: significance for mode of action and implications for therapy of cerebral malaria.
2009,
Pubmed
Combe,
Clonal conditional mutagenesis in malaria parasites.
2009,
Pubmed
Crabb,
Characterization of promoters and stable transfection by homologous and nonhomologous recombination in Plasmodium falciparum.
1996,
Pubmed
Dahlström,
Diversity of the sarco/endoplasmic reticulum Ca(2+)-ATPase orthologue of Plasmodium falciparum (PfATP6).
2008,
Pubmed
Dondorp,
Artemisinin resistance in Plasmodium falciparum malaria.
2009,
Pubmed
Eastman,
Artemisinin-based combination therapies: a vital tool in efforts to eliminate malaria.
2009,
Pubmed
Eckstein-Ludwig,
Artemisinins target the SERCA of Plasmodium falciparum.
2003,
Pubmed
,
Xenbase
Fidock,
Cycloguanil and its parent compound proguanil demonstrate distinct activities against Plasmodium falciparum malaria parasites transformed with human dihydrofolate reductase.
1998,
Pubmed
Fidock,
Recent highlights in antimalarial drug resistance and chemotherapy research.
2008,
Pubmed
Gelb,
Drug discovery for malaria: a very challenging and timely endeavor.
2007,
Pubmed
Golenser,
Current perspectives on the mechanism of action of artemisinins.
2006,
Pubmed
Goodyer,
Plasmodium falciparum: a simple, rapid method for detecting parasite clones in microtiter plates.
1997,
Pubmed
Haynes,
The Fe2+-mediated decomposition, PfATP6 binding, and antimalarial activities of artemisone and other artemisinins: the unlikelihood of C-centered radicals as bioactive intermediates.
2007,
Pubmed
Haynes,
Artemisinins: activities and actions.
2004,
Pubmed
Haynes,
Artemisone--a highly active antimalarial drug of the artemisinin class.
2006,
Pubmed
Hoppe,
Antimalarial quinolines and artemisinin inhibit endocytosis in Plasmodium falciparum.
2004,
Pubmed
Ibrahim,
Polymorphism of PfATPase in Niger: detection of three new point mutations.
2009,
Pubmed
Jambou,
Resistance of Plasmodium falciparum field isolates to in-vitro artemether and point mutations of the SERCA-type PfATPase6.
2005,
Pubmed
Jung,
Three-dimensional structure of Plasmodium falciparum Ca2+ -ATPase(PfATP6) and docking of artemisinin derivatives to PfATP6.
2005,
Pubmed
Kremsner,
Antimalarial combinations.
,
Pubmed
Krishna,
Artemisinins: their growing importance in medicine.
2008,
Pubmed
Le Roch,
Discovery of gene function by expression profiling of the malaria parasite life cycle.
2003,
Pubmed
Li,
Yeast model uncovers dual roles of mitochondria in action of artemisinin.
2005,
Pubmed
Mamoun,
A set of independent selectable markers for transfection of the human malaria parasite Plasmodium falciparum.
1999,
Pubmed
Menegon,
Detection of novel point mutations in the Plasmodium falciparum ATPase6 candidate gene for resistance to artemisinins.
2008,
Pubmed
Nagamune,
Artemisinin induces calcium-dependent protein secretion in the protozoan parasite Toxoplasma gondii.
2007,
Pubmed
Naik,
The binding modes and binding affinities of artemisinin derivatives with Plasmodium falciparum Ca2+-ATPase (PfATP6).
2011,
Pubmed
Noedl,
Evidence of artemisinin-resistant malaria in western Cambodia.
2008,
Pubmed
Noedl,
In vitro antimalarial activity of azithromycin, artesunate, and quinine in combination and correlation with clinical outcome.
2007,
Pubmed
O'Neill,
A medicinal chemistry perspective on artemisinin and related endoperoxides.
2004,
Pubmed
Omara-Opyene,
Genetic disruption of the Plasmodium falciparum digestive vacuole plasmepsins demonstrates their functional redundancy.
2004,
Pubmed
Pandey,
Artemisinin, an endoperoxide antimalarial, disrupts the hemoglobin catabolism and heme detoxification systems in malarial parasite.
1999,
Pubmed
Reed,
Pgh1 modulates sensitivity and resistance to multiple antimalarials in Plasmodium falciparum.
2000,
Pubmed
Riganti,
Artemisinin induces doxorubicin resistance in human colon cancer cells via calcium-dependent activation of HIF-1alpha and P-glycoprotein overexpression.
2009,
Pubmed
Robert,
The antimalarial drug artemisinin alkylates heme in infected mice.
2005,
Pubmed
Sidhu,
Chloroquine resistance in Plasmodium falciparum malaria parasites conferred by pfcrt mutations.
2002,
Pubmed
Sidhu,
pfmdr1 mutations contribute to quinine resistance and enhance mefloquine and artemisinin sensitivity in Plasmodium falciparum.
2005,
Pubmed
Sidhu,
Decreasing pfmdr1 copy number in plasmodium falciparum malaria heightens susceptibility to mefloquine, lumefantrine, halofantrine, quinine, and artemisinin.
2006,
Pubmed
Stockwin,
Artemisinin dimer anticancer activity correlates with heme-catalyzed reactive oxygen species generation and endoplasmic reticulum stress induction.
2009,
Pubmed
Tahar,
Molecular epidemiology of malaria in Cameroon. XXVIII. In vitro activity of dihydroartemisinin against clinical isolates of Plasmodium falciparum and sequence analysis of the P. falciparum ATPase 6 gene.
2009,
Pubmed
Toovey,
Effect of artemisinins and amino alcohol partner antimalarials on mammalian sarcoendoplasmic reticulum calcium adenosine triphosphatase activity.
2008,
Pubmed
Toyoshima,
Crystal structure of the calcium pump of sarcoplasmic reticulum at 2.6 A resolution.
2000,
Pubmed
Toyoshima,
Crystal structure of the calcium pump with a bound ATP analogue.
2004,
Pubmed
Uhlemann,
A single amino acid residue can determine the sensitivity of SERCAs to artemisinins.
2005,
Pubmed
,
Xenbase
Valderramos,
Identification of a mutant PfCRT-mediated chloroquine tolerance phenotype in Plasmodium falciparum.
2010,
Pubmed
White,
Qinghaosu (artemisinin): the price of success.
2008,
Pubmed
Witkowski,
Increased tolerance to artemisinin in Plasmodium falciparum is mediated by a quiescence mechanism.
2010,
Pubmed
Woodrow,
Artemisinins.
2005,
Pubmed
Wu,
Localization and quantification of endoplasmic reticulum Ca(2+)-ATPase isoform transcripts.
1995,
Pubmed
del Pilar Crespo,
Artemisinin and a series of novel endoperoxide antimalarials exert early effects on digestive vacuole morphology.
2008,
Pubmed
ter Kuile,
Plasmodium falciparum: in vitro studies of the pharmacodynamic properties of drugs used for the treatment of severe malaria.
1993,
Pubmed
